Search
- Page Path
- HOME > Search
Review Article
- Lipid variability in patients with diabetes mellitus
- Jeongmin Lee, Seung-Hwan Lee
- Cardiovasc Prev Pharmacother. 2023;5(4):126-133. Published online October 25, 2023
- DOI: https://doi.org/10.36011/cpp.2023.5.e18
- 10,637 View
- 171 Download
- 3 Citations
-
Abstract
PDF - Diabetic dyslipidemia is characterized by hypertriglyceridemia, low high-density lipoprotein cholesterol (HDL-C), elevated low-density lipoprotein cholesterol (LDL-C), and the predominance of small dense LDL particles caused by insulin resistance in patients with type 2 diabetes mellitus (DM) or insulin deficiency in patients with type 1 DM. Dyslipidemia is a major risk factor for atherosclerotic cardiovascular disease in individuals with DM, and lowering lipid levels can reduce the associated morbidity and mortality. The current guidelines for dyslipidemia management recommend an LDL-C goal lower than 55 to 100 mg/dL, depending on the underlying risk factors. However, greater visit-to-visit variability in cholesterol levels might be an independent predictor of major adverse cardiovascular events, high incidence of atrial fibrillation, poor renal outcomes, and cognitive dysfunction in patients with DM. This review focuses on the clinical implications of lipid variability in patients with DM.
-
Citations
Citations to this article as recorded by
- Visit-to-visit lipid variability and adverse kidney events in real-world type 2 diabetes patients
Hsuan-Yu Su, Yi-Hsin Chang, Chen-Yi Yang, Wei-Hung Lin, Huang-Tz Ou
Diabetes Research and Clinical Practice.2025; 222: 112093. CrossRef - Antidiabetic and Toxicological Evaluation of Ehretia asperula Leaf Extract in Diabetic Mice
Yen D. H. Nguyen, Tran Chi Linh, Nguyen Trong Tuan, Luu Thai Danh, Dai Thi Xuan Trang
Chemistry & Biodiversity.2025;[Epub] CrossRef - The use of statins in patients with type 2 diabetes mellitus
Vera Morari, Carolina Andriuta, Elena Babalau, Mariana Malevan, Natalia Porcereanu
Public Health, Economy and Management in Medicine.2024; (5(102)): 59. CrossRef
- Visit-to-visit lipid variability and adverse kidney events in real-world type 2 diabetes patients
First
Prev
